Lorbrena
Lorbrena ingredients
| Active ingredient | Strength |
|---|---|
| Lorlatinib | 100 mg/1, 25 mg/1 |
What Lorbrena is used for
The FDA lists the approved uses on the official label (below). In the EU, lorlatinib is approved as Lorviqua for:
Lorviqua as monotherapy is indicated for the treatment of adult patients with anaplastic lymphoma kinase (ALK)?positive advanced non-small cell lung cancer (NSCLC) previously not treated with an ALK inhibitor. Lorviqua as monotherapy is indicated for the treatment of adult patients with ALK-positive advanced NSCLC whose disease has progressed after: alectinib or ceritinib as the first ALK tyrosine kinase inhibitor (TKI) therapy; or crizotinib and at least one other ALK TKI.
EU wording from the European Medicines Agency; US approved uses can differ.
Key facts
- Brand
- Lorbrena
- Generic name
- Lorlatinib
- Made by
- Pfizer Laboratories Div Pfizer Inc
- Forms
- Tablet, Film Coated
- Given
- Oral
- Drug class
- Kinase Inhibitor
- FDA approval
- New drug application (NDA) NDA210868
- On the US market since
- 2018
Official information
- Lorbrena prescribing information (FDA label) on DailyMed
- MedlinePlus drug information (search for Lorlatinib)
In India
- Lorlatinib: 2 brands in India
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Lorbrena?
Lorbrena (Lorlatinib) is a cancer medicine made by Pfizer Laboratories Div Pfizer Inc, approved by the US FDA.
What are the ingredients of Lorbrena?
Lorbrena contains Lorlatinib (100 mg/1, 25 mg/1).
Is Lorbrena approved in Europe?
The same active substance is approved in the EU as Lorviqua.
From the FDA National Drug Code directory (open.fda.gov, public domain) and the European Medicines Agency medicines list. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, USA